評論
打印
In 2009, two years after the federal guilty plea,
馬薩諸塞州檢察官援引的電子郵件往來記錄顯示，
Mortimer D.A. Sackler, a board member, demanded to know why the company wasn’t selling more opioids,
2009年，在簽署聯邦認罪協議兩年后，
email traffic cited by Massachusetts prosecutors showed.
莫蒂默·薩克勒，普渡制藥公司董事，還要求了解公司為何沒有售出更多阿片類藥物。
In 2011, as states looked for ways to curb opioid prescriptions,
2011年，各州都在想辦法控制阿片類藥物處方的數量時，
family members peppered the sales staff with questions about how to expand the market for the drugs.
薩克勒家族的成員還向銷售人員提出了大量有關如何擴大阿片類藥物市場的問題。
Mortimer asked if they could sell a generic version of OxyContin in order to "capture more cost sensitive patients," according to one email.
一封電子郵件顯示，莫蒂默曾詢問（銷售人員)他們是否可以銷售普通版的奧施康定，以“俘獲更多對藥費敏感的患者”。
Kathe, his half sister, suggested studying patients who had switched to OxyContin
莫蒂默同父異母的妹妹凱特曾建議，對那些改用奧施康定的病人展開研究，
to see if they could find patterns that could help them win new customers,
看看能否借此找到幫助他們贏得新客戶的模式。
according to court filings in Massachusetts.
馬薩諸塞州的法庭文件顯示。
The family’s statement said they were just acting as responsible board members,
該家族的聲明稱，他們那么做只是在盡董事會成員的責任，
raising questions about "business issues that were highly relevant to doctors and patients."
對“與醫生和病人高度相關的商業問題”提出他們的疑問。
In July 2011, Mortimer and Kathe’s cousin Dr. Richard Sackler,
2011年7月，莫蒂默和凱特的堂兄理查德·薩克勒醫生,
who had stepped down as Purdue’s president several years earlier but remained an influential board member,
幾年前，他辭去了普渡制藥總裁一職，但依然是公司頗有分量的董事,
went into the field with a sales representative to promote opioids to doctors,
曾在銷售代表的陪同下親自找醫生促銷阿片類藥物，
though some in the company were concerned that his involvement could run afoul of regulators,
雖然公司有員工擔心他的親力親為會和監管機構發生沖突，
according to documents in the Massachusetts case.
麻薩諸塞州的訴訟文件顯示。
When he returned, he argued in an email to Purdue’s vice president for sales
回去后，他在給普渡制藥負責銷售的副總裁的一封郵件中辯稱，
that a legally required warning about opioids wasn’t needed,
沒有必要按照法律要求對阿片類藥物（的危險性）發出警告，
and that it "implies a danger of untoward reactions and hazards that simply aren’t there."
不然反而“相當于在暗示藥物有事實上根本不存在的不良反應和危險”。
(The family’s statement disputed that, saying that Richard supported accurate labeling,
（該家族的聲明對此作出了反駁，聲稱理查德是支持明確在標簽里注明藥物風險的，
and merely questioned where on the label the warning should appear.
只是對警告應該放在標簽上的哪個位置提出了疑問。
The statement also said he had not been out in the field with sales representatives since well before the launch of OxyContin, in 1996.)
聲明還說，1996年奧施康定推出之前，他就早已不再和銷售代表一起跑業務了。)
In 2014, Raymond Sackler, now deceased, sent three other family members a confidential memo
2014年，現已去世的雷蒙德·薩克勒向家族其他三名成員發送了一份機密備忘錄，
about Purdue’s strategy for placing patients on high doses of opioids for extended periods of time.
內容是關于普渡制藥如何讓患者長時間服用高劑量阿片類藥物的策略。
The memo noted that doctors had argued against the practice,
備忘錄指出，醫生們反對這種做法，
but that Purdue had beaten back efforts to impose caps on doses,
但公司壓制了對劑量設置上限的努力，
according to the Massachusetts complaint.
馬薩諸塞州的起訴書顯示。
The next year, Jonathan Sackler, then a board member,
次年，時任董事會成員的喬納森·薩克勒
sought information about how public health campaigns to curb opioid addiction would affect OxyContin sales.
曾搜集過有關遏制阿片類藥物成癮的公共衛生運動將對奧施康定的銷售造成怎樣的影響方面的信息。
In 2017, he pushed to develop a new opioid, and asked the staff to present a plan at the next Purdue board meeting.
2017年，他力推開發一種新的阿片類藥物，還要求員工在下一次普渡制藥董事會會議上提交一份相關的方案。
譯文由可可原創，僅供學習交流使用，未經許可請勿轉載。
